Senior Director, Compliance Training

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$244K-$305K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$81,650 U.S. median for this role

Projected growth (BLS Employment Projections)

+6.9% - Faster than average

236% above the BLS role benchmark for human resources aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 13-1071 - Human Resources aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Hr From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Director, Compliance Training Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director of Compliance Training will lead the strategy, design, and execution of a global compliance training program for a biotechnology organization. This role is responsible for fostering a culture of ethics and compliance by delivering engaging, risk-based training aligned with regulatory requirements and industry best practices. The ideal candidate brings deep expertise in life sciences compliance, adult learning methodologies, and global training program management. This role will work closely with Learning & Development, Corporate Communications, Legal, HR, and business stakeholders to integrate compliance and legal training into broader enterprise learning, communications, and change-management efforts. - Develop and implement a comprehensive, risk-based compliance training strategy aligned with business objectives and regulatory expectations (e.g., FDA, OIG, DOJ, EMA). - Serve as a key advisor to the Vice President, Compliance and senior leadership on training-related compliance risks and mitigation strategies. - Continuously assess and

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.